Immunotherapy in Hodgkin Lymphoma: Present Status and Future Strategies

Cancers
Theodoros P VassilakopoulosKostas Konstantopoulos

Abstract

Although classical Hodgkin lymphoma (cHL) is usually curable, 20-30% of the patients experience treatment failure and most of them are typically treated with salvage chemotherapy and autologous stem cell transplantation (autoSCT). However, 45-55% of that subset further relapse or progress despite intensive treatment. At the advanced stage of the disease course, recently developed immunotherapeutic approaches have provided very promising results with prolonged remissions or disease stabilization in many patients. Brentuximab vedotin (BV) has been approved for patients with relapsed/refractory cHL (rr-cHL) who have failed autoSCT, as a consolidation after autoSCT in high-risk patients, as well as for patients who are ineligible for autoSCT or multiagent chemotherapy who have failed ≥ two treatment lines. However, except of the consolidation setting, 90-95% of the patients will progress and require further treatment. In this clinical setting, immune checkpoint inhibitors (CPIs) have produced impressive results. Both nivolumab and pembrolizumab have been approved for rr-cHL after autoSCT and BV failure, while pembrolizumab has also been licensed for transplant ineligible patients after BV failure. Other CPIs, sintilimab and tisleli...Continue Reading

References

Apr 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A OsterborgH Mellstedt
Mar 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A SuredaUNKNOWN Grupo Español de Linformas/Transplante Autólogo de Médula Osea Spanish Cooperative Group
Jan 10, 2002·Medical Oncology·G A PangalisM P Siakantaris
Jan 25, 2002·The New England Journal of Medicine·Bertrand CoiffierChristian Gisselbrecht
Feb 15, 2003·Blood·Bradley C EkstrandSandra J Horning
Mar 2, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A SuredaUNKNOWN Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea Cooperative Group
Nov 7, 2006·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Navneet S MajhailLinda J Burns
Jan 24, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Harmonization Project on Lymphoma
Jan 24, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Malik E JuweidUNKNOWN Imaging Subcommittee of International Harmonization Project in Lymphoma
May 23, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephen M AnsellPeter Borchmann
Mar 22, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B SirohiA Horwich
May 27, 2009·British Journal of Haematology·Andres Forero-TorresAjay K Gopal
Nov 5, 2010·The New England Journal of Medicine·Anas YounesAndres Forero-Torres
Mar 8, 2011·Cell·Douglas Hanahan, Robert A Weinberg
Oct 4, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Panayotis KaloyannidisAchilles Anagnostopoulos
Feb 22, 2012·Blood·Yvette L KasamonRichard F Ambinder
Mar 29, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anas YounesRobert Chen
Aug 10, 2012·The New England Journal of Medicine·H C Kluin-NelemansM H Dreyling
Mar 20, 2013·Seminars in Hematology·Theodoros P Vassilakopoulos, Maria K Angelopoulou
May 29, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C MartínezUNKNOWN Lymphoma Working Party of the European Group for Blood and Marrow Transplantation (EBMT) and the Gruppo Italiano Trapianto d
Dec 18, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Catherine M BollardCliona M Rooney
Feb 12, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ranjana H AdvaniNancy L Bartlett
Mar 20, 2014·Journal of Hematology & Oncology·Nancy L BartlettAndres Forero-Torres
May 2, 2014·Frontiers in Immunology·Ole Audun Werner HaabethBjarne Bogen
Jun 20, 2014·Current Hematologic Malignancy Reports·Francesca Montanari, Catherine Diefenbach
Aug 13, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonT Andrew Lister
Sep 19, 2014·Annals of Hematology·A SalihogluB Ferhanoglu
Nov 2, 2014·Blood·Dieter HoelzerUNKNOWN German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia
Dec 9, 2014·The New England Journal of Medicine·Stephen M AnsellPhilippe Armand

❮ Previous
Next ❯

Citations

Oct 5, 2019·Journal of Clinical Medicine·Valli De ReMaurizio Mascarin
Feb 29, 2020·Therapeutic Advances in Hematology·Theodoros P VassilakopoulosMaria K Angelopoulou
Nov 26, 2020·Leukemia & Lymphoma·Vassilios PapadakisTheodoros P Vassilakopoulos
Sep 15, 2019·Cellular Signalling·Paul DentJohn F Hancock
Apr 2, 2021·The Lancet Oncology·Theodoros P Vassilakopoulos
Aug 28, 2021·Deutsche medizinische Wochenschrift·Anna ReischerMichael von Bergwelt-Baildon
Aug 31, 2021·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Cédric Rossi, René-Olivier Casasnovas
Nov 6, 2021·Leukemia & Lymphoma·Aislinn Macklin-DohertyAnthony Swerdlow

❮ Previous
Next ❯

Methods Mentioned

BETA
ICE

Clinical Trials Mentioned

NCT02661503
NCT00129753
NCT01030900
NCT00441818
NCT02061761

Software Mentioned

ECHELON
AETHERA
R
BEACOPPesc

Related Concepts

Related Feeds

Bacterial Vaginosis

Bacterial vaginosis can increase the risk of sexually transmitted infections and in rare cases lead to pelvic inflammatory diseases. Discover the latest research on Bacterial Vaginosis here.